2016
DOI: 10.18632/oncotarget.9004
|View full text |Cite
|
Sign up to set email alerts
|

Heterogeneous PSMA expression on circulating tumor cells - a potential basis for stratification and monitoring of PSMA-directed therapies in prostate cancer

Abstract: The prostate specific membrane antigen (PSMA) is the only clinically validated marker for therapeutic decisions in prostate cancer (PC). Characterization of circulating tumor cells (CTCs) obtained from the peripheral blood of PC patients might provide an alternative to tissue biopsies called “liquid biopsy”. The aim of this study was to develop a reliable assay for the determination of PSMA on CTCs. PSMA expression was analyzed on tissue samples (cohort one, n = 75) and CTCs from metastatic PC patients (cohort… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

3
51
1
2

Year Published

2017
2017
2023
2023

Publication Types

Select...
10

Relationship

1
9

Authors

Journals

citations
Cited by 78 publications
(57 citation statements)
references
References 27 publications
3
51
1
2
Order By: Relevance
“…“Liquid biopsy” on circulating tumor cells (CTC) characterization has been studied to address the question of PSMA-targeted therapeutic decision [ 25 ]. But PSMA profiling is not only determined by the cell line.…”
Section: Discussionmentioning
confidence: 99%
“…“Liquid biopsy” on circulating tumor cells (CTC) characterization has been studied to address the question of PSMA-targeted therapeutic decision [ 25 ]. But PSMA profiling is not only determined by the cell line.…”
Section: Discussionmentioning
confidence: 99%
“…PSMA is a 100 KDa type II membrane protein expressed in all forms of prostate tissues, including prostate carcinoma [32,33]. Therefore, we assessed these markers in our BPH patients to evaluate the possible progression of disease.…”
Section: Discussionmentioning
confidence: 99%
“…Despite the intrinsic limitation that CTCs are rare, 10 analysis of CTCs has allowed a non-invasive, real-time molecular characterization of cancer in patients with metastatic disease 11 , 12 and has successfully been used to predict response to Docetaxel and Prednisone in patients with metastatic castration resistant PC (mCRPC). 13 Additionally, nuclear expression of the androgen receptor variant V7 (AR-V7) in CTCs seems to report response to taxanes.…”
Section: Introductionmentioning
confidence: 99%